Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension

Table 19

Kinetic data analysis of Nateglinide (sustain release) layer in bilayer tablet.

Zero order		First order		Higuchi		Korsemeyer
Time (hr)	Cum. %release	Time (hr)	Log cum. %remaining	Sqrt. of time	Cum. %drug release	Log of time	Log cum. %release
0	0	0	0	0	0	0	0
1	9.9	1	0	1	8.46	0	0.927370363
2	15.68	2	1.96161091	1.4142136	17.69	0.301029996	1.247727833
3	26.42	3	1.9154526	1.7320508	25.29	0.477121255	1.402948829
4	32.2	4	1.87337874	2	36.66	0.602059991	1.564192461
5	39.63	5	1.80167806	2.236068	45.46	0.698970004	1.657629431
6	47.06	6	1.73671513	2.4494897	53.32	0.77815125	1.726890141
7	53.67	7	1.66913085	2.6457513	64.23	0.84509804	1.807737922
8	60.27	8	1.55351894	2.8284271	72.7	0.903089987	1.861534411
9	75.14	9	1.43616265	3	80.42	0.954242509	1.905364069
10	81.74	10	1.29181269	3.1622777	87.18	1	1.940416865
11	92.48	11	1.10788803	3.3166248	91.42	1.041392685	1.961041217
12	96.92	12	0.93348729	3.4641016	97.22	1.079181246	1.987755617